Jazz Pharmaceuticals plc Stock price

Equities

JAZZ

IE00B4Q5ZN47

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
120.4 USD -0.07% Intraday chart for Jazz Pharmaceuticals plc -2.97% -2.10%
Sales 2024 * 4.1B Sales 2025 * 4.39B Capitalization 7.51B
Net income 2024 * 481M Net income 2025 * 649M EV / Sales 2024 * 2.57 x
Net Debt 2024 * 3B Net Debt 2025 * 1.61B EV / Sales 2025 * 2.08 x
P/E ratio 2024 *
18.1 x
P/E ratio 2025 *
12.3 x
Employees 2,800
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.18%
More Fundamentals * Assessed data
Dynamic Chart
JPMorgan Raises Jazz Pharmaceuticals' Price Target to $190 From $170, Maintains Overweight Rating MT
Piper Sandler Adjusts Price Target on Jazz Pharmaceuticals to $188 From $171, Maintains Overweight Rating MT
Transcript : Jazz Pharmaceuticals plc - Special Call
Stifel Raises Jazz Pharmaceuticals' Price Target to $230 From $225, Maintains Buy Rating MT
H.C. Wainwright Cuts Price Target on Jazz Pharmaceuticals to $200 From $204, Maintains Buy Rating MT
Transcript : Jazz Pharmaceuticals plc Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 02:00 PM
Transcript : Jazz Pharmaceuticals plc Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-04-2024 10:30 AM
UBS Adjusts Jazz Pharmaceuticals Price Target to $131 From $135, Maintains Neutral Rating MT
Barclays Cuts Price Target on Jazz Pharmaceuticals to $230 From $235, Maintains Overweight Rating MT
Needham Cuts Price Target on Jazz Pharmaceuticals to $220 From $225, Maintains Buy Rating MT
Tranche Update on Jazz Pharmaceuticals plc's Equity Buyback Plan announced on November 8, 2016. CI
Jazz Pharmaceuticals Swings to Q4 Non-GAAP Earnings, Revenue Rises; 2024 Guidance Set, Shares Down After Hours MT
Transcript : Jazz Pharmaceuticals plc, Q4 2023 Earnings Call, Feb 28, 2024
(JAZZ) JAZZ PHARMACEUTICALS Expects Fiscal Year 2024 EPS Range $18.15 - $19.35 MT
(JAZZ) JAZZ PHARMACEUTICALS Forecasts Fiscal Year 2024 Revenue $4B-$4.2B MT
More news

Latest transcript on Jazz Pharmaceuticals plc

1 day-0.07%
1 week-2.97%
Current month+1.28%
1 month-7.15%
3 months-2.38%
6 months-8.10%
Current year-2.10%
More quotes
1 week
117.71
Extreme 117.71
123.68
1 month
115.45
Extreme 115.45
125.95
Current year
113.55
Extreme 113.55
134.17
1 year
111.25
Extreme 111.2506
147.98
3 years
111.25
Extreme 111.2506
189.00
5 years
86.88
Extreme 86.88
189.00
10 years
86.88
Extreme 86.88
194.73
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 03-02-28
President 52 20-03-15
Chief Tech/Sci/R&D Officer 57 19-05-28
Members of the board TitleAgeSince
Chief Executive Officer 60 03-02-28
Director/Board Member 66 13-05-12
Director/Board Member 62 08-12-31
More insiders
Date Price Change Volume
24-03-28 120.4 -0.07% 409,944
24-03-27 120.5 +2.19% 471,653
24-03-26 117.9 -2.37% 1,689,780
24-03-25 120.8 -0.84% 597,609
24-03-22 121.8 -1.85% 691,817

Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT

More quotes
Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company's lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
120.4 USD
Average target price
188.8 USD
Spread / Average Target
+56.78%
Consensus
  1. Stock
  2. Equities
  3. Stock Jazz Pharmaceuticals plc - Nasdaq